Merck's Sac-TMT Drug Meets Endpoints in Phase 3 Endometrial Cancer Trial

Merck announced that its experimental drug, Sac-TMT, successfully met both primary endpoints in its Phase 3 clinical trial for endometrial cancer. This marks a significant step forward in the drug's development.